tiprankstipranks
Top Stocks
U.S. Stock Market OverviewTop Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
Top ETFs by AUMSPY ETFQQQ ETF
Stock Comparison
Energy StocksOil StocksBest Value StocksAirline StocksElectric Vehicle StocksMATANA Stocks
New
Bank StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
Global Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsPre-Market BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Top ETFs by AUM
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
U.S. Markets
Market Movers
Expert Center
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
Top ETFs by AUM
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Energy Stocks
EV Stocks
Crypto News
Dividend Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Pre-Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

IMGO Stock Latest News

Merck completes tender offer to acquire Imago BioSciences
The FlyMerck completes tender offer to acquire Imago BioSciences
17d ago
MRK
IMGO
Imago BioSciences:1st participant dosed in bomedemstat/ruxolitinib study for MF
The FlyImago BioSciences:1st participant dosed in bomedemstat/ruxolitinib study for MF
1M ago
IMGO
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
Press ReleasesImago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
1M ago
IMGO
Eight new option listings and one option delisting on December 14th
The FlyEight new option listings and one option delisting on December 14th
1M ago
CBNK
IMGO
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
Press ReleasesImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
2M ago
IMGO
Imago BioSciences presents data from Phase 2 study of bomedemstat in ET
The FlyImago BioSciences presents data from Phase 2 study of bomedemstat in ET
2M ago
IMGO
Imago BioSciences presents data from ongoing Phase 2 study of bomedemstat
The FlyImago BioSciences presents data from ongoing Phase 2 study of bomedemstat
2M ago
IMGO
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
Press ReleasesImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
2M ago
IMGO
Imago BioSciences says 1st patient dosed in bomedemstat combo study for AML
The FlyImago BioSciences says 1st patient dosed in bomedemstat combo study for AML
2M ago
IMGO
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
Press ReleasesImago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
2M ago
IMGO
Imago BioSciences downgraded to Hold from Buy at Stifel
The FlyImago BioSciences downgraded to Hold from Buy at Stifel
2M ago
IMGO
Merck Snaps Up Imago for $1.35 Billion; Stock Up 100%
Market NewsMerck Snaps Up Imago for $1.35 Billion; Stock Up 100%
2M ago
MRK
IMGO
Imago BioSciences reports Q3 EPS (50c), consensus (44c)
The FlyImago BioSciences reports Q3 EPS (50c), consensus (44c)
3M ago
IMGO
Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates
Press ReleasesImago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates
3M ago
IMGO
Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Press ReleasesImago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
5M ago
IMGO
Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Press ReleasesImago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference
6M ago
IMGO
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
Press ReleasesImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
8M ago
IMGO
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022
Press ReleasesImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022
8M ago
IMGO
Imago BioSciences to Host Virtual Investor Event
Press ReleasesImago BioSciences to Host Virtual Investor Event
8M ago
IMGO
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.